HAVCR2 and acute myeloid leukemia: The detection of TIM3 in myeloid malignancies cells, in particular MDS [127] and AML leukemic stem cells [128], along with the discovery of the prognostic negative significance of its overexpression in T cells [129,130,131,132], led to the development of drugs targeting this pathway.